Mepolizumab biosimilar(Bio Thera Solutions)

美泊利单抗生物类似药（百奥泰）

Report date: 2023/09/13 09:14:49

Base Information

Drug NameMepolizumab biosimilar(Bio Thera Solutions)
Drug Alias Name美泊利珠单抗注射液BAT2606BAT-2606
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionInterleukin-5 inhibitors
TargetsInterleukin-5
Therapy Area/IndicationsAutoimmune DiseasesNasal PolypsAsthma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBio-Thera Solutions Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNasal PolypsAsthma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A